ID   14433_1
SY   14433
DR   cancercelllines; CVCL_JY31
DR   Wikidata; Q54581913
RX   PubMed=25862976;
RX   PubMed=31150822;
CC   Doubling time: 2-3 days (PubMed=25862976).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2853Ter (c.8557A>T); ClinVar=VCV000372573; Zygosity=Homozygous (PubMed=25862976; PubMed=31150822).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=25862976; PubMed=31150822).
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=31150822
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D12S391: 21
ST   D13S317: 11
ST   D16S539: 12
ST   D18S51: 18
ST   D19S433: 14,15
ST   D1S1656: 12,19.3
ST   D21S11: 29,30
ST   D2S1338: 22
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D6S1043: 20
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 21
ST   Penta D: 9,10
ST   Penta E: 14
ST   TH01: 8
ST   TPOX: 10,11
ST   vWA: 17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   61Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 05-10-23; Version: 11
RX   PubMed=25862976; DOI=10.1016/j.canlet.2015.03.040;
RA   Kreuzinger C., Gamperl M., Wolf A., Heinze G., Geroldinger A.,
RA   Lambrechts D., Boeckx B., Smeets D., Horvat R., Aust S., Hamilton G.,
RA   Zeillinger R., Castillo-Tong D.C.;
RT   "Molecular characterization of 7 new established cell lines from high
RT   grade serous ovarian cancer.";
RL   Cancer Lett. 362:218-228(2015).
RX   PubMed=31150822; DOI=10.1016/j.canlet.2019.05.032;
RA   Kreuzinger C., von der Decken I., Wolf A., Gamperl M., Koller J.,
RA   Karacs J., Pfaffinger S., Bartl T., Reinthaller A., Grimm C.,
RA   Singer C.F., Braicu E.I., Cunnea P., Gourley C., Smeets D., Boeckx B.,
RA   Lambrechts D., Perco P., Horvat R., Berns E.M.J.J., Castillo-Tong D.C.;
RT   "Patient-derived cell line models revealed therapeutic targets and
RT   molecular mechanisms underlying disease progression of high grade
RT   serous ovarian cancer.";
RL   Cancer Lett. 459:1-12(2019).